Every 8-K that Haemonetics Corporation (HAE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HAE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAE filings page.
Haemonetics Corporation (HAE) updated investors on its non-exclusive supply agreement with CSL Plasma. CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States. CSL expects to complete the rollout by the end of calendar year 2027 and currently anticipates a transition at all of its current U.S. plasma collection centers.
The rollout’s scope and timing remain subject to change under the agreement, and Haemonetics and CSL are still determining implementation details. Haemonetics is not updating its previously issued fiscal 2027 guidance at this time; it expects to provide an update on the agreement’s anticipated impact on fiscal 2027 results with its second fiscal quarter earnings call in November 2026.
Haemonetics Corporation entered into a non-exclusive supply agreement with CSL Plasma Inc. under which CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables for U.S. plasma collection centers. The agreement does not include minimum purchase commitments, and Haemonetics currently expects CSL to transition only a portion of its U.S. centers, with the scope and timing of that transition still undetermined. Because of this uncertainty, Haemonetics is not revising its fiscal 2027 guidance at this time and plans to discuss the anticipated financial impact of the agreement in conjunction with its second fiscal quarter earnings call in November 2026.
Haemonetics reported first quarter fiscal 2027 revenue of $339.4 million, up 5.6% year over year with 5.9% organic growth. Apheresis revenue was $191.3 million and MedSurg revenue $148.1 million, both growing mid‑single digits, led by Plasma and Blood Management Technologies, while Interventional Technologies also returned to growth.
GAAP gross margin held at 59.8%. Operating income was $57.5 million with a 16.9% margin. Net income was $33.0 million and earnings per diluted share $0.72, slightly above $0.70 a year earlier despite a higher tax rate of 30.6%. Adjusted EPS was $1.14 on a 23.4% adjusted operating margin.
Cash flow from operating activities rose to $52.3 million and free cash flow to $39.1 million, supporting a cash balance of $223.4 million. Management raised fiscal 2027 guidance to 5–8% reported revenue growth and 4–7% organic growth, with 50–100 basis points of adjusted operating margin expansion and free cash flow conversion of about 80%.
Haemonetics Corporation reported that its Board of Directors elected Martin Madaus as a director, effective July 24, 2026. He is expected to join the Audit Committee and the Governance and Compliance Committee and, as a non-employee director, will receive compensation consistent with the directors’ compensation program, including an annual equity award of approximately $200,000, and will enter into the company’s standard indemnification agreement.
At the 2026 annual meeting, shareholders holding 42,051,106 of 45,445,983 entitled shares were represented, a 92.53% quorum. Shareholders elected eight directors, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm. They also approved amendments and restatements of the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending its term through 2036, and the 2007 Employee Stock Purchase Plan, also extended through 2036.
Haemonetics Corporation is reorganizing how it reports its business segments. The company will move from three reportable segments to two, combining the Plasma and Blood Center segments into a single Apheresis segment and renaming the Hospital segment as MedSurg.
Haemonetics will begin reporting under this new structure with the first quarter of fiscal 2027, which began on March 29, 2026. To help comparison, it has posted a supplemental presentation with recast quarterly historical revenue for fiscal years 2024, 2025 and 2026, plus a recast of previously issued fiscal 2027 revenue guidance. The company explicitly states that this presentation does not reaffirm or update its fiscal 2027 guidance; any updates will come on the first quarter fiscal 2027 earnings call.
Haemonetics reported fourth quarter and fiscal 2026 results and issued fiscal 2027 guidance. Fourth quarter revenue was $346.4 million, up 4.8%, while fiscal 2026 revenue was $1.33 billion, down 2.0% from fiscal 2025.
Due mainly to a $77.2 million impairment related to Attune Medical and other charges, the company posted a fourth quarter net loss of $20.1 million, or $(0.44) per diluted share, versus earnings of $1.17 a year earlier. Adjusted diluted EPS for the quarter rose to $1.29, and fiscal 2026 adjusted diluted EPS was $4.96.
Operating cash flow for fiscal 2026 was $293.2 million and free cash flow was $209.9 million. In the fourth quarter, the company repurchased 1.58 million shares for $100 million, leaving $325 million under its authorization. For fiscal 2027, Haemonetics guides to 4–7% reported revenue growth, 3–6% organic revenue growth and about 80% free cash flow conversion.
Haemonetics Corporation reports that long-serving director Charles J. Dockendorff has informed the company he will not stand for re-election at its 2026 Annual Meeting of Shareholders. He has served on the Board since 2014 and is a member of the Audit Committee and the Governance and Compliance Committee.
Mr. Dockendorff will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision not to stand for re-election is not the result of any disagreement with Haemonetics.
Haemonetics Corporation has repaid in full its 0.00% Convertible Senior Notes due 2026 at their scheduled maturity. The company paid an aggregate of $300,000,000 in cash, equal to the outstanding principal on the notes, using a combination of cash on hand and borrowings under its revolving credit facility.
No noteholders chose to convert their notes into equity before the cut-off date, so the entire principal was settled in cash rather than shares. The capped call transactions that were entered into when the notes were originally issued have now expired in line with their terms as the notes reached maturity.
Haemonetics Corporation filed a current report to inform investors that on February 12, 2026, it published its 2024-2025 Corporate Responsibility Report. The report is available in the Corporate Responsibility section of the company’s website, highlighting its disclosure on environmental, social, and governance-related topics.
The company also clarifies that the information shared under this item is being furnished under Regulation FD rather than filed, meaning it is not subject to Section 18 liability of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings.
Haemonetics Corporation filed a current report stating that it issued a press release with financial results for the third quarter and nine months ended December 27, 2025. The press release, dated February 5, 2026, is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
Haemonetics Corporation has completed the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company developing next-generation technology for percutaneous vessel closure. Haemonetics acquired all outstanding equity interests of Vivasure for €100 million, or approximately €52 million net of certain prior investments, loans and other customary closing adjustments. The agreement also includes up to an additional €85 million in contingent consideration tied to sales growth and other milestones, subject to adjustment for specified prior investments and loan amounts. Haemonetics financed the transaction entirely with available cash on hand.
Haemonetics Corporation furnished a press release announcing financial results for the second quarter ended September 27, 2025 and the first half of fiscal 2026. The release is attached to a Form 8‑K as Exhibit 99.1 under Item 2.02. The company notes this information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act, and is not incorporated by reference. The filing also includes the Inline XBRL cover page file as Exhibit 104.